Trio exome sequencing as the stand-alone first-tier testing for prenatal diagnosis

Haibo Li, Lulu Yan, Yuxin Zhang, Min Li, Jiangyang Xue, Liyun Tian, Juan Cao, Shanshan Wu, Yanling Dong, Yuying Zhu, Hongmei Zhou, Shuangshuang Shen, Xiayuan Xu, Guosong Shen, Xueping Shen, Penglong Chen, Yanting Xu, Dandan Cai, Yuchao Wang, Shu Fang, Changshui Chen, Zhaojing ZhengmedRxiv 2025 · DOI

Abstract

Whole exome sequencing (WES) is increasingly utilized in prenatal diagnosis for fetuses with structural abnormalities. However, evidence supporting its use as a first-tier genetic test for all pregnancies referred for invasive prenatal procedures remains limited. We conducted a multi-center prospective study enrolling 1,382 pregnancies across seven centers in China. Participants were divided into a CMA group (traditional indications) and a CTW group (expanded indications). Trio-WES yielded an overall diagnostic yield of 17.22%, with an incremental yield of 7.38% for variants not detected by CMA. Notably, trio-WES showed 100% concordance with CMA for reportable cytogenomic events. Our findings support the use of prenatal trio-WES as a stand-alone first-tier genetic test for all pregnancies referred for invasive prenatal diagnosis, regardless of indication.

Introduction

For over a decade, Chromosomal Microarray Analysis (CMA) has served as the gold standard first-tier test for invasive prenatal diagnosis. CMA is highly effective at identifying copy number variants (CNVs)—large-scale deletions or duplications of genetic material. However, CMA is inherently limited by its resolution; it cannot detect single-nucleotide variants (SNVs) or small insertions/deletions (Indels), which are the primary causes of many monogenic disorders.

Currently, Whole Exome Sequencing (WES) is typically employed as a secondary test, reserved for cases where CMA returns a negative result despite the presence of fetal structural anomalies. This sequential testing strategy often delays diagnosis and increases costs. Furthermore, it may miss significant genetic findings in pregnancies referred for non-structural reasons, such as advanced maternal age or abnormal serum screening. This study investigates whether Trio-WES can effectively replace CMA as the primary, stand-alone diagnostic tool for all invasive prenatal procedures.

Methods

This prospective, multi-center study enrolled 1,382 singleton pregnancies across seven prenatal diagnosis centers in China. The cohort was stratified into two primary groups:

  1. CMA Group: Pregnancies with traditional indications where CMA is the standard recommendation (e.g., advanced maternal age, abnormal serum screening, or parental anxiety).
  2. CTW Group: Pregnancies with expanded indications where both CMA and WES are typically recommended (e.g., ultrasound-detected structural anomalies).

The researchers utilized a "Trio" approach, performing exome sequencing on the fetus and both biological parents simultaneously. This method allows for the rapid identification of de novo mutations and the determination of inheritance patterns (recessive or X-linked). To ensure analytical validity, CMA and Trio-WES were performed in parallel on 1,141 cases. The bioinformatics pipeline utilized GATK-based calling for SNVs and specialized algorithms to detect CNVs and Uniparental Disomy (UPD) directly from the exome data.

Key Results

Diagnostic Yield and Incremental Gain

The study achieved an overall diagnostic yield of 17.22% (238/1,382 cases). Crucially, Trio-WES provided an incremental diagnostic yield of 7.38% by identifying pathogenic SNVs and Indels that would have been entirely missed by CMA.

Even within the "low-risk" CMA group—pregnancies without visible structural anomalies—Trio-WES provided a diagnostic yield of 4.02%. This finding challenges the current practice of limiting WES to fetuses with structural defects, suggesting that a significant portion of genetic conditions in the general referral population remains undetected under current protocols.

Concordance and Superior Resolution

Trio-WES demonstrated 100% concordance with CMA for all reportable cytogenomic events. Beyond matching CMA's performance, Trio-WES showed superior resolution in specific areas, identifying six cases of Uniparental Disomy (UPD) and three cases of exon-level deletions that were below the detection threshold of the microarrays used in the study.

Clinical Decision-Making

The genetic findings significantly influenced clinical outcomes. Termination of pregnancy (TOP) rates were markedly higher in cases involving de novo or biallelic pathogenic variants (84.17%) compared to those with inherited variants (35.71%). This underscores the importance of the "Trio" context in helping parents and clinicians interpret the severity and recurrence risk of genetic findings.

Discussion

The results of this multi-center study suggest that Trio-WES is a robust, "all-in-one" solution for prenatal diagnosis. By capturing both the large-scale CNVs traditionally found by CMA and the small-scale SNVs found by sequencing, Trio-WES provides a more comprehensive genetic profile in a single step.

Limitations

While the study is large, the authors note that the subgroup of pregnancies with "CMA-only" indications was relatively modest, and larger cohorts may be needed to further refine the utility of WES in low-risk populations. Additionally, the 3-month postpartum follow-up period may not be sufficient to identify late-onset conditions or neurodevelopmental delays associated with variants of uncertain significance (VUS). Finally, the study did not report on fetal secondary findings, an area that requires further ethical and professional consensus.

Conclusion

Trio-WES is a highly effective stand-alone first-tier test for prenatal diagnosis. Its ability to detect a wide spectrum of genetic variants—from large chromosomal shifts to single-base changes—with high accuracy and incremental yield supports its adoption as the primary diagnostic tool for all pregnancies undergoing invasive testing, regardless of the initial clinical indication.

Paper Citation: Li, H., et al. "Trio exome sequencing as the stand-alone first-tier testing for prenatal diagnosis." medRxiv (Preprint), 2025.

Summary updated

Abstract

Abstract BACKGROUND Whole exome sequencing (WES) is increasingly utilized in prenatal diagnosis of fetus with structural abnormality. However, evidence supporting its use as a first-tier genetic test for all pregnancies referred for invasive prenatal procedures remains limited. METHODS We conducted a multi-center prospective study enrolling 1,382 pregnancies from seven prenatal diagnosis centers all around China. Participants were divided into two groups based on clinical indications: those for whom CMA testing was traditionally recommended (CMA group) and those for whom CMA and WES were sequentially or concurrently recommended (CTW group) according to their indications. After excluding 200 pregnancies terminated prior to genetic test reporting, the cohort included 1,182 cases undergoing independent trio-WES and CMA testing. The primary outcome was determined through follow-up of at least 3 months after delivery. RESULTS Trio-WES yielded an overall diagnostic yield of 17.22%, with an incremental yield of 7.38% for SNVs/Indels not detected by CMA. Even for subjects in the CMA group, there’s a diagnostic yield of 4.02%, arising from SNVs/Indels that would be missed by CMA. Trio-WES showed a 100% concordance with CMA on detection of reportable cytogenomic events, with unique advantages over CMA in 6 cases with UPD and 3 cases with exon-level deletion. Importantly, WES results, whether positive, negative or uncertain, significantly impact clinical decision-making for pregnancy. CONCLUSIONS Our findings support the use of prenatal trio-WES as a stand-alone first-tier genetic test for all pregnancies referred for invasive prenatal diagnosis, regardless of indication.
BibTeX
@misc{li2025trio,
  author = {Haibo Li and Lulu Yan and Yuxin Zhang and Min Li and Jiangyang Xue and Liyun Tian and Juan Cao and Shanshan Wu and Yanling Dong and Yuying Zhu and Hongmei Zhou and Shuangshuang Shen and Xiayuan Xu and Guosong Shen and Xueping Shen and Penglong Chen and Yanting Xu and Dandan Cai and Yuchao Wang and Yuchao Wang and Shu Fang and Changshui Chen and Zhaojing Zheng and Changshui Chen},
  title = {{Trio exome sequencing as the stand-alone first-tier testing for prenatal diagnosis}},
  year = {2025},
  doi = {10.1101/2025.07.23.25331964},
  howpublished = {medRxiv},
}
Figure